Grail Shares Rally on Favorable FDA Staff Review
US FDA staff reviewers raised no major safety or accuracy concerns regarding Grails Galleri multi-cancer blood test. The positive preliminary findings sent company shares surging ahead of an upcoming advisory committee meeting.
Xurve View
Insights:
Xurve View
GRAIL INC shares surged 35% on Monday after United States regulators flagged no major accuracy or safety concerns for its multi-cancer blood test. The findings arrived ahead of an external panel review on Wednesday regarding premarket approval for the screening tool. Grail's test generated $136.8M in revenue across the country last year.
